Apalutamide

證據等級: L5

預測適應症: 10 個

Apalutamide: From Prostate Cancer to Male Reproductive Organ Cancer

One-Sentence Summary

Apalutamide (Erleada®) is a second-generation androgen receptor (AR) inhibitor globally established for prostate cancer treatment—having received FDA approval for non-metastatic castration-resistant prostate cancer (2018) and metastatic castration-sensitive prostate cancer (2019)—yet remains unregistered in Singapore. The TxGNN model predicts it may be effective for Male Reproductive Organ Cancer, with 50 clinical trials and 18 publications currently supporting this direction. This indication carries the strongest evidence level in the dataset (L1), driven by multiple completed Phase 3 RCTs, and the recommended decision is Proceed with Guardrails pending local regulatory authorization.

Quick Overview

Item	Content
Original Indication	Prostate cancer (globally approved; not registered in Singapore)
Predicted New Indication	Male Reproductive Organ Cancer
TxGNN Prediction Score	97.41%
Evidence Level	L1
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Singapore regulatory database. Based on the published scientific record, Apalutamide is a competitive androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of AR, preventing androgen binding, blocking AR nuclear translocation, and inhibiting downstream AR-mediated transcriptional activation. Originally developed as ARN-509, it was specifically engineered to overcome the partial agonist activity of first-generation antiandrogens such as bicalutamide—particularly relevant in the castration-resistant setting where AR is frequently overexpressed or constitutively activated.

Prostate cancer is fundamentally an androgen-driven malignancy. The androgen receptor remains the principal oncogenic driver even after systemic testosterone suppression, a phenomenon that underpins the transition to castration-resistant disease. Apalutamide targets this central oncogenic pathway by directly antagonising AR signalling, thereby suppressing tumour cell proliferation, DNA synthesis, and survival. This mechanism is active across multiple stages of the prostate cancer continuum: high-risk localised disease, non-metastatic castration-resistant disease (nmCRPC), and metastatic hormone-sensitive disease (mHSPC).

The TxGNN model's prediction of "male reproductive organ cancer" as a high-confidence indication (score 97.41%) is entirely consistent with Apalutamide's established clinical profile. The landmark Phase 3 SPARTAN trial demonstrated an approximately 24-month improvement in metastasis-free survival for nmCRPC, and the Phase 3 TITAN trial confirmed superior overall survival when apalutamide was added to androgen deprivation therapy in mHSPC. The drug's absence from the Singapore market reflects a regulatory gap rather than an evidence gap.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03767244	Phase 3	Active, Not Recruiting	2,517	Double-blind RCT of apalutamide + ADT vs placebo + ADT before and after radical prostatectomy in high-risk localised/locally advanced PCa; primary endpoints: pathological complete response rate and metastasis-free survival
NCT02489318	Phase 3	Active, Not Recruiting	1,052	TITAN study: apalutamide + ADT vs ADT alone in metastatic hormone-sensitive PCa; final analysis confirmed significant improvement in both radiographic PFS and overall survival
NCT04557059	Phase 3	Active, Not Recruiting	694	Apalutamide added to radiotherapy + LHRHa in high-risk hormone-sensitive PCa; evaluating PSMA-PET-based metastatic progression delay vs RT + LHRHa alone
NCT06592924	Phase 3	Recruiting	830	Docetaxel addition to ARPI in mCSPC patients with suboptimal PSA response; tests treatment escalation in poor first-line responders
NCT03124433	Phase 2	Completed	30	NEAR trial: neoadjuvant apalutamide monotherapy + radical prostatectomy in D'Amico intermediate/high-risk PCa; demonstrated tumour downstaging and pathological responses
NCT01171898	Phase 1/2	Completed	127	Original proof-of-concept study of ARN-509 (apalutamide) in advanced CRPC; established dose selection and initial efficacy across three patient cohorts, forming the basis for Phase 3 development
NCT03436654	Phase 2	Active, Not Recruiting	102	Multi-arm neoadjuvant study combining apalutamide + abiraterone + prednisone + ADT before surgery in very high-risk localised and low-volume metastatic PCa
NCT04295447	Phase 2	Active, Not Recruiting	190	Adjuvant apalutamide vs standard of care after radical prostatectomy in high-risk PCa; primary endpoint: biochemically recurrence-free survival
NCT02867020	Phase 2	Completed	128	Three-arm randomised comparison of abiraterone + ADT, apalutamide alone, and abiraterone + apalutamide in hormone-naïve locally advanced or metastatic PCa
NCT05202301	Observational	Completed	13,779	Large real-world study on medication adherence and discontinuation patterns among prostate cancer patients initiating second-generation AR inhibitors including apalutamide

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33914595	2021	Phase 3 RCT	J Clin Oncol	TITAN final analysis: apalutamide + ADT significantly improved OS and rPFS in mCSPC; survival benefit maintained after placebo-to-apalutamide crossover
31150574	2019	Phase 3 RCT	N Engl J Med	TITAN primary analysis: apalutamide + ADT vs placebo + ADT in metastatic castration-sensitive PCa; significant rPFS and OS advantage at first interim analysis
29420164	2018	Phase 3 RCT	N Engl J Med	SPARTAN study: apalutamide extended median metastasis-free survival by approximately 24 months vs placebo in high-risk non-metastatic CRPC
32907777	2021	Phase 3 RCT	Eur Urol	SPARTAN final OS analysis: apalutamide improved overall survival in nmCRPC; validated MFS as a surrogate endpoint for OS in this disease setting
36858151	2023	Phase 3 Analysis	Ann Oncol	TITAN PSA kinetics sub-analysis: deep and rapid PSA decline with apalutamide + ADT independently associated with improved OS; ultralow PSA identified as a prognostic marker in mCSPC
38261983	2024	Phase 3 RCT	J Clin Oncol	PRESTO (AFT-19): androgen blockade intensification with apalutamide in high-risk biochemically relapsed castration-sensitive PCa following radical prostatectomy; assessed whether intensification improves outcomes
39417629	2025	Comparative Cohort	The Prostate	Real-world multicenter comparison of abiraterone, enzalutamide, and apalutamide differential efficacy and safety in metastatic hormone-sensitive PCa
36167599	2023	Phase 2 RCT	Eur Urol	ARNEO trial: randomised neoadjuvant degarelix ± apalutamide prior to radical prostatectomy; assessed pathological downstaging and biomarker response in high-risk PCa
35091711	2022	Phase 2	Prostate Cancer Prostatic Dis	NEAR trial results: single-arm Phase II of neoadjuvant apalutamide monotherapy + radical prostatectomy in D'Amico intermediate-/high-risk PCa; pathological efficacy and downstaging outcomes
32930958	2020	Review	Drugs	Comprehensive drug review: apalutamide mechanism of action, Phase 3 clinical evidence (TITAN), pharmacokinetics, and safety profile in metastatic castration-sensitive PCa

Singapore Market Information

Apalutamide is currently not registered in Singapore. No product authorisations are on file with the Health Sciences Authority (HSA), and no apalutamide-containing products are commercially available locally. Regulatory authorisation is required before the drug can be prescribed or distributed in Singapore.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Second-generation Androgen Receptor Inhibitor (non-cytotoxic, non-myelosuppressive mechanism of action)
Myelosuppression Risk	Low (AR inhibitors do not suppress bone marrow; standard haematological monitoring recommended as part of routine oncology follow-up)
Emetogenicity Classification	Low (oral agent; nausea is infrequent in clinical trials; routine antiemetic prophylaxis is not required)
Monitoring Items	Thyroid function (TSH), liver function tests, blood pressure, fasting lipid profile, bone mineral density (with long-term ADT co-administration); ECG if QT-prolonging agents are co-prescribed
Handling Protection	Standard oral anticancer agent handling guidelines apply; dedicated cytotoxic compounding facilities are generally not required; follow local institutional SOPs

Safety Considerations

Drug Interactions: Apalutamide is a potent inducer of CYP3A4 and may substantially reduce plasma concentrations of co-administered CYP3A4-sensitive substrates, including tyrosine kinase inhibitors, anticoagulants, immunosuppressants, and certain statins. A comprehensive medication reconciliation is essential prior to initiation and at each review.
Key Adverse Events to Monitor: Skin reactions and rash (reported in approximately 24% of patients in the TITAN trial), fatigue, hypothyroidism, falls and fractures (associated with concurrent ADT use), and cardiovascular events require proactive monitoring and patient counselling.

Complete prescribing information—including boxed warnings, full contraindications, and a comprehensive drug interaction table—is not available in the current dataset. Please refer to the approved package insert (e.g., FDA-approved Erleada® Prescribing Information or the most current EMA-approved SmPC) for complete safety guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Apalutamide has established L1 evidence from multiple completed Phase 3 RCTs—SPARTAN for nmCRPC and TITAN for mCSPC—demonstrating clinically meaningful and statistically significant improvements in both metastasis-free survival and overall survival. The drug is approved in the US, EU, Japan, and other major markets, yet remains unavailable to Singapore patients with prostate cancer, one of the most prevalent male malignancies in the region. The evidence base is robust; the primary barrier is regulatory.

To proceed, the following is needed:

HSA Regulatory Submission: Prepare and submit a New Drug Application (NDA) or abridged application to the Health Sciences Authority (HSA) Singapore, leveraging existing FDA/EMA approval dossiers to expedite review
Complete Safety Documentation: Obtain the full prescribing information including boxed warnings, contraindications, and a comprehensive DDI table, which are currently absent from the local regulatory dataset
CYP3A4 DDI Risk Management Protocol: Develop institutional guidance for managing strong CYP3A4 induction interactions in the Singapore patient population, with particular attention to polypharmacy settings common in elderly oncology patients
Risk Management Plan (RMP): Prepare a Singapore-specific RMP addressing key identified risks: falls and fractures, cardiovascular events, hypothyroidism, and skin reactions
Asian Subgroup Data Review: Evaluate available Asian patient subgroup data from TITAN and SPARTAN to confirm appropriateness for the Singapore population and determine whether additional bridging studies are required
Formulary and Reimbursement Strategy: Assess cost-effectiveness for potential inclusion in national subsidy schemes (e.g., Medication Assistance Fund) or institutional hospital drug formularies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.